PDE5A and cancer: In the overall pan-cancer analysis of male‐predominant solid organ malignancies, PDE5 inhibitor exposure was associated with significantly improved OS at all measured timepoints compared with controls (1‐year OS 98.6% vs 95.7%, p<0.001; 3‐year OS 96.1% vs 90.7%, p<0.001; 5‐year OS 93.8% vs 86.6%, p<0.001; HR, 0.42 [95% CI, 0.41–0.44]; Figure 1, Table 3).